Regentis Biomaterials Expands SAGE Clinical Trial of GelrinC™ for Knee Pain
October 23, 2018 PRINCETON, N.J. & OR AKIVA, Israel--(BUSINESS WIRE)--Regentis Biomaterials today announced it has expanded the SAGE clinical trial of GelrinC™ for the treatment of articular cartilage damage in the knee to 11 U.S. sites. GelrinC is an investigational device being evaluated as a treatment to help the body regrow cartilage in the knee. Articular cartilage